GLP-1RA Use May Lower Overall Cancer Risk but Increase Kidney Cancer Risk in Obese Patients: JAMA
USA: A new study published in JAMA Oncology has revealed that glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for type 2 diabetes management and weight loss, may have an impact on cancer risk among adults with obesity. The research, led by Hao Dai and colleagues from the Department of Biostatistics and Health Data Science, Indiana […]